Background: Activation of phospholipase D (PLD) is an important but poorly understood component of receptor-mediated signal transduction responses and regulated secretion. We recently reported the cloning of the human gene encoding PLD1; this enzyme has low basal activity and is activated by protein kinase C and the small GTP-binding proteins, ADP-ribosylation factor (ARF), Rho, Rac and Cdc42. Biochemical and cell biological studies suggest, however, that additional and distinct PLD activities exist in cells, so a search was carried out for novel mammalian genes related to PLD1.
Background
Activation of phosphatidylcholine-specific phospholipase D (PLD) correlates with both receptor-mediated signal transduction responses [1, 2] and regulated secretion [3] [4] [5] [6] [7] . The effects of inhibiting PLD activity have suggested that PLD plays an important role in both processes. An additional line of evidence linking PLD to these processes is that PLD has been shown to be activated by protein kinase C ␣ (PKC␣) and members of the Rho and ADPribosylation factor (ARF) families of small GTP-binding proteins; ARF directs key steps in intracellular protein traffic (as, less directly, do Rho and PKC␣) [5, [7] [8] [9] , and Rho family members effect changes in cell motility and morphology [10] .
Once activated, PLD generates phosphatidic acid (PA). The mechanism by which PA affects secretion and morphology has not been established, although several interesting hypotheses have been proposed [2, 5, 11] . In addition, PA can be metabolized to form lipids, such as diacylglycerol and lysophosphatidic acid, which have proven roles as intracellular and intercellular messengers, respectively (reviewed in [12] ).
A number of different partially purified PLD activities have been described in recent years. One well-described set of activities requires phosphatidylinositol 4,5-bisphosphate (PIP 2 ), is inhibited by oleate, and is activated by PKC␣ and the small GTP-binding proteins Rho and ARF (reviewed in [13] ). Individual PLD activities of this type, enriched from different subcellular fractions, have been reported to be activated with different efficacies by ARF, Rho and PKC [14] [15] [16] [17] . A distinct, second type of PLD activity has also been described which requires oleate but not PIP 2 [18] , and which is not activated by ARF [19] . At least one of these activities has been identified with the recent cloning of the gene encoding human PLD1 [20] .
The PLD1 gene encodes a well-described PLD activity present in numerous tissues and cell lines [20] . PLD1 has a low basal rate of catalysis that is sharply increased by a varied set of regulators including PKC␣, ARF and RhoA family members [20, 21] . PLD1 activity requires PIP 2 and is inhibited by oleate. Purified recombinant PLD1 can be activated independently by members of each of the known categories of PLD activator (PKC␣, ARF and Rho), underscoring the complex nature of PLD1 activation and regulation. These properties of PLD1, in combination with earlier studies on PLD activity, have prompted us to hypothesize that PLD1 participates both in regulating secretion, in coordination with ARF and PKC␣, and in propagating signal transduction responses, such as cytoskeletal reorganization, through interaction with RhoA family members [6] .
Nonetheless, in addition to those already mentioned above, PLD activities with distinct properties that are difficult to reconcile with the in vitro properties of PLD1 have been reported in association with selected signal transduction events and with Src-and Ras-mediated oncogenic transformation [22] [23] [24] [25] [26] . In support of the argument for there being additional mammalian PLD1-related isoforms, the available evidence suggests that PLD1-related enzymes in other species are quite varied in their regulatory properties and requirements; the PLD1 homolog in yeast is active in the absence of PKC and small G proteins [12, 27] , and PLD1 homologs and activities in plants do not require PIP 2 [28, 29] . Alternatively, regulatory processes, such as the post-transcriptional or post-translational modification of PLD1, or the variable presence of PLD activators or inhibitors, might account for the different PLD activities found in mammalian cells. A splice variant of PLD1 occurs in which a 38 amino-acid exon is excluded [21] , although the regulatory properties of the two proteins generated by the alternately spliced cDNAs appear indistinguishable.
To investigate whether distinct PLD enzymes exist, we searched for novel PLD1-related mammalian genes. We have identified PLD2, a second mammalian phosphatidylcholine-specific PLD. Our results show that PLD2 is regulated in a very different manner from PLD1, localizes to a separate region of the cell, and when overexpressed promotes different cellular responses than PLD1. These findings suggest that PLD1 and PLD2 mediate distinct cellular processes.
Results and discussion

Cloning of PLD2
To search for PLD1-related genes, the PLD1 cDNA coding region was used as a probe to screen a mouse embryonic library at reduced stringency. Approximately 20 cDNA clones encoding an overlapping but incomplete coding region were isolated, and the remaining sequence generated by 5′ rapid amplification of cDNA ends (RACE) [30] . The PLD2 coding region encodes a 932 amino-acid protein (Fig. 1 ) that exhibits extensive homology to PLD1 throughout its length, particularly in regions thought to be required for catalysis [12, 20, 31] . Less similarity is observed between the amino termini, which are not required for catalysis in either PLD1 or PLD2 (T-C.S. and M.A.F., unpublished observations). In addition, PLD2 does not encode a PLD1-like 'loop' region, which is found in PLD1 but not in PLDs from non-animal species [12, 20] . Overall, the human PLD1 and mouse PLD2 (mPLD2) proteins are 51% identical; by comparison, the human and mouse PLD1 proteins are 92% identical (W.C.C. and M.A.F., unpublished observations). Several human short expressed sequence tags (ESTs) encoding overlapping peptide sequences highly similar to mPLD2 were entered into Genbank subsequent to our cloning of mPLD2. Assuming that these ESTs encode parts of human PLD2, human and mouse PLD2 proteins are about 96% identical over the partial regions available for comparison (data not shown). All of the ESTs presently listed in Genbank that show significant homology to the cloned PLDs appear to correspond to either PLD1 or PLD2.
Unexpected PLD2 basal activity in vitro
To begin to investigate whether PLD1 and PLD2 are functionally redundant, we expressed and purified PLD2 and examined its basal and activated rates of catalysis. We previously reported that PLD1 could be expressed using baculovirus and purified [20, 21] . PLD2 was similarly expressed and purified; no proteins other than PLD1 or PLD2 were detectable in the purified preparations by either Coomassie blue (data not shown) or silver staining (Fig. 2a) . As reported before, PLD1 has an extremely low level of basal activity and can be activated by PKC␣ and members of the Rho and ARF families; the effects of these activators on PLD1 are synergistic ( Fig. 3a; and see [21] ). In the presence of all three activators, PLD1 activity is increased about 250-fold over basal levels.
In contrast, PLD2 unexpectedly exhibits a high basal activity, about 1500-fold greater than that of PLD1 (Fig.  3b) . Moreover, addition of the factors that activate PLD1 -PKC␣ and members of the Rho and ARF familiesdo not further increase PLD2 activity, suggesting that isolated PLD2 is already fully active. Rac1 and Cdc42, which activate PLD1 [21] , also do not further activate PLD2 (data not shown). The actual catalytic mechanisms employed by PLD1 and PLD2 appear to be similar; both require PIP 2 as a cofactor and exhibit similar substrate specificity and requirements for cations ( Fig. 3b and data not shown). Purification of endogenous mPLD2 from adult tissues using immunoaffinity chromatography has been achieved, and in vitro analysis of this PLD2 yields similar results (A.J.M., unpublished observations). This excludes the possibility that the unexpected regulatory properties of our recombinant PLD2 derive from an aberrant composite cDNA produced during the cloning of mPLD2.
Our results suggest that PLD2 is active in the default state, in contrast to PLD1 which is basally inactive. Although we cannot definitively rule out the possible copurification of a PLD2 activator, this appears very unlikely for the following reasons. First, immunopurification of PLD1 from sf9 cell extracts using the protocol described for PLD2 results in essentially complete depletion of PLD1 activators, which have to be added back to restore activity, but immunopurification of PLD2 does not result in a substantial decrease in PLD2 activity. Second, PLD1 effectors maximally activate PLD1 only at relatively high concentrations (0.1-1 mM; see [21] ), but silver staining of the purified PLD2 protein indicates that contaminating proteins are not detectable, and are certainly not present in stoichiometric amounts or anything approaching millimolar concentrations. Third, PLD2 activity in vitro is not dependent on GTP␥S or phorbol ester (PMA), ruling out the most obvious types of activator.
PLD2 is highly active in vivo
The assay used to measure PLD activity in vitro is well characterized and accepted [32] , but is not representative of the physiological cellular environment in several respects. One possible explanation for the high basal level of PLD2 activity in vitro might be that it behaves anomalously in this assay, which is optimized for studying PLD1-like activities. To determine whether the high PLD2 basal activity observed in vitro is indicative of its behavior in vivo, we examined PLD2 activity in intact cells. COS-7 cells were transiently transfected with either PLD1 or PLD2 expression vectors and assayed using the transphosphatidylation method, which measures PLD's unique propensity to convert phosphatidylcholine into phosphatidylbutanol in the presence of butanol [33] .
Control transfected COS-7 cells had almost undetectable PLD activity (Fig. 4a) , consistent with our prior observations for this cell line [20] . Transfection of these cells with PLD1 did not greatly increase the observed activity, suggesting that PLD1 is largely inactive under our culture conditions in the absence of stimulation. However, substantial activity was observed after transfection with PLD2 (Fig. 4a) , demonstrating that the cellular environment in vivo supports spontaneous Comparison of human PLD1 (hPLD1) and mouse PLD2 (mPLD2) amino-acid sequences. Boxed regions indicate identical amino acids. The five regions conserved in prokaryote and eukaryote PLD homologs are highlighted in yellow [12, 20] , and invariant amino acids required for catalysis are highlighted in orange (T-C.S. and M.A.F., unpublished observations). Dashes indicate gaps in the sequence alignment where there are no residues in PLD2 that correspond to the PLD1 'loop' region. The mPLD2 amino-acid and nucleotide sequences have been deposited in Genbank under the accession number U87557.
high-level PLD2 activity. Unlike the in vitro experiments ( Fig. 3) , we cannot determine whether PLD2 activity in the cellular environment is regulated positively or negatively by unknown cellular factors, though availability of PIP 2 may be rate-limiting for PLD2 activity in vivo. Nonetheless, taken together with the in vitro data, our data suggest that PLD2 overexpressed in the cellular environment is active in the absence of stimulatory factors required by PLD1.
One possible explanation for the differential activity of PLD1 and PLD2 in vivo might be that PLD1 was not expressed as well as PLD2 after transfection of COS-7 cells. Western blot and immunofluorescence analysis of the transfected cells indicated that both proteins were present in moderate amounts (data not shown). However, such analyses cannot reveal whether the proteins are functional. The presence of functional PLD1 protein was demonstrated by using conditions known to trigger PLD1 activation and re-examining the relative amounts of phosphatidylbutanol generated in cells producing each PLD protein. Bypassing ligand stimulation, PLD1 can be activated in vivo by first using PMA to activate PKC. PMA addition was accompanied by rapid accumulation of phosphatidylbutanol in both PLD1-and PLD2-transfected cells (Fig. 4b ). Compared to cells that were not stimulated with PMA, PLD1-specific catalysis increased 10-15-fold, whereas PLD2-specific catalysis increased only 2-fold (Fig. 4c ).
These results support the findings in vitro by demonstrating that PLD2 is active in vivo in unstimulated cells, in contrast to PLD1 which is not basally active. In addition, the results again suggest that PLD2 is largely refractory to PKC activation: even the modest two-fold increase in PLD2 activity on PMA addition could result from mechanisms other than a direct interaction with PKC. Although PKC␣ activates PLD [34, 35] and PLD1 [21] in vitro in a non-catalytic (non-ATP-dependent) manner, PLD activation in vivo is frequently inhibited when PKC catalytic activity is blocked [34, 36] , implying that part of the PKC response in vivo involves phosphorylation of a PLD regulator -for example, PKC phosphorylation inhibits Ras GTPase-activating protein (Ras-GAP) which activates Ras, which then activates PLD2 exhibits a novel form of regulated activity in vitro. The activities of (a) PLD1 and (b) PLD2 were determined in the presence of various combinations of PLD1 activators. Activity was measured using a headgroup-release assay [20] in the presence of optimal concentrations of PLD proteins and activators. Dose-response curves with the activators have previously been performed for PLD1 [20, 21] . Dose-response curves were performed for PLD2 and generated qualitatively similar results to those shown in this figure. Activation of PLD1 by the small GTP-binding proteins is dependent on the inclusion of GTP␥S in this assay. Stimulation of PLD1 by PKC is enhanced in this assay by the presence of phorbol ester (PMA), which activates PKC. However, the PKC-mediated stimulation is mediated by PKC's regulatory domain and is not ATP-dependent. We observed a lack of effect of the small GTPbinding proteins or PKC␣ on PLD2 activity, regardless of whether GTP␥S or PMA were present (data not shown). The amounts of PLD proteins used were adjusted to prevent saturation of the assay. NA indicates no addition. Similar results were observed in assays of cell extracts prepared from COS-7 cells transiently transfected with either PLD1 or PLD2 mammalian expression vectors, except that the PLD1 basal activity was higher (about 15% of the ARF-stimulated PLD1 activity), as a result of limiting quantities of endogenous activators in the cell lysates (data not shown). As previously reported for PLD1 [20] , PLD2 activity also requires PIP 2 (b, last column). Recombinant PLD proteins were expressed using baculovirus and affinity purified using anti-PLD1 and anti-PLD2 peptide antisera. (a) After purification, PLD1 and PLD2 were the only proteins detectable by silver staining. Approximately 100 ng of each protein was separated by electrophoresis; silver staining reveals PLD1 more effectively than PLD2. (b) Western blot analysis of samples of PLD1 and PLD2, using the PLD1-and PLD2-specific antisera, confirming the identities of the bands visible in the silver-stained gel. The approximate positions and sizes (in kDa) of marker proteins are indicated. other small GTP-binding proteins [37] . PIP 2 levels and availability are also altered indirectly after PKC activation. These results do suggest, however, that PLD2 could account for the numerous reports of agonist-stimulated PKC-independent PLD activity [1] .
PLD2-specific inhibition in vitro
The striking regulatory differences between PLD1 and PLD2 are surprising in light of the similarity of the two proteins ( Fig. 1) . Identification of a constitutively active PLD was unexpected: PLD has been studied extensively, but no such activity has previously been purified. Instead, only PLD1-like activities have been reported. This paradox raised the possibility that endogenous PLD2 activity might normally be masked by negative regulators. According to this model, PLD2 activity would become transiently derepressed upon ligand stimulation.
To pursue this hypothesis, we searched in a variety of mammalian cell lines and tissues for modulators of PLD2 activity. Preliminary studies indicated that several tissue extracts contained cytosolic factors that inhibited the activity of purified PLD2 in vitro. Bovine brain was a particularly rich source of such inhibitory activity and was used to generate an enriched preparation of the inhibitor(s). Extracts from brain were subjected to chromatographic fractionation, and the fractions were assayed for the presence of PLD2 inhibitors.
Analysis of the fractions revealed the presence of several PLD1 and PLD2 inhibitors, one of which is relatively specific for PLD2 (Fig. 5) . The major protein detected in this inhibitory fraction by Coomassie blue staining is approximately 18 kDa (Fig. 5a ), although inhibition by other proteins present at low or undetectable concentrations cannot be ruled out. The inhibitor is proteinaceous, ruling out non-protein inhibitors such as oleate. Although the size of the major protein in the inhibitory fraction is similar to that of the small GTP-binding proteins, several lines of evidence suggest that the inhibitor is very unlikely to be one of them. First, the inhibitor does not stimulate PLD1 in the presence of GTP␥S (data not shown). Second, the inhibitory activity is not GTP␥S-dependent. Finally, unlike all small GTP-binding proteins reported thus far, the inhibitor is stable to heating at 70°C. The mechanism of action of the inhibitor is unlikely to be non-specific, as PLD1 and PLD2 are indistinguishable in terms of cation, phospholipid and phosphatidylinositol requirements ( the correct cell type, PLD2 is subject to negative regulation in vivo. PLD1 and PLD2 might both play roles in signal transduction, but might do so through opposing mechanisms -activation versus derepression. The identity of a hypothetical effector(s) that could oppose the action of the inhibitor remains to be determined. With respect to the tissue source of the inhibitor, PLD2 is expressed at relatively high levels in the brain (W.C.C. and M.A.F., unpublished observations), although whether the inhibitor and PLD2 are expressed in the same cells and subcellular locations remains an important issue for future studies.
Two inhibitors of cellular PLD1-like activity have recently been reported [38, 39] . Both inhibitors are relatively large -300 kDa and 150 kDa. One inhibitor has been identified as fodrin [38] , and the other as synaptojanin [39] . Fodrin has a pleckstrin homology domain and additionally inhibits phospholipase C [38] ; synaptojanin hydrolyzes PIP 2 . Thus, both inhibitors are likely to act by regulating the availability of PLD cofactors or substrates, and neither is a good candidate for a PLD2-specific inhibitor. On the basis of its selectivity and size, the inhibitor we describe here is clearly different from fodrin and synaptojanin.
Subcellular localization of PLD1 and PLD2
PLD activities have been enriched from almost every region of the cell, including the plasma membrane [15, 16] , cytoplasm [15, 16] , nucleus [40] and 'endomembranes' [16] , which consist of the Golgi [9] , endoplasmic reticulum (ER) [17] and endosomes. Many of these activities have been reported to be preferentially activated by one or more of the various PLD effectors. To begin to determine which of these activities PLD1 and PLD2 are likely to account for, we examined the subcellular localization of influenza-epitope-tagged PLD1 and PLD2 proteins using microinjection of reporter plasmids into rat embryo fibroblasts [41] .
PLD1 was found exclusively in a peri-nuclear region of the cell (Fig. 6a) . The staining pattern is consistent with the Golgi, ER, and late endosomes, but not the cytoplasm or plasma membrane. PLD1 was not observed to be concentrated in the nucleus or on the nuclear membrane, although we cannot rule out the presence of low levels of PLD1 on the nuclear membrane. A number of recent reports have suggested that an ARF- [5, 7, 8] and PKC- [42] activated PLD plays a role in promoting vesicular budding and secretion. The localization of PLD1 and its activation properties suggest that PLD1 may have a major role in the regulation of peri-nuclear intravesicular membrane traffic. Ligand-receptor stimulation causes translocation of ARF to Golgi membranes and subsequent PLD activation [43] . Similar findings have suggested that Rho and PKC also translocate to the Golgi or ER after agonist stimulation. Taken together, these findings imply that PLD1's responsiveness to ARF, PKC␣ and Rho family members may reflect a coupling of signal transduction and regulated secretion, rather than a role for PLD1 in constitutive secretion or in cytoskeletal reorganization at the plasma membrane [6] . In support of this, serum stimulation of PLD1-overexpressing cells did not provoke a visible phenotype suggestive of cytoskeletal reorganization (Fig. 6b and data not shown; serum contains factors that stimulate endogenous PLD1-like activity [1] ).
In contrast, PLD2 was predominantly associated with the plasma membrane in quiescent cells (Fig. 6c) . The periphery of the injected cells was relatively irregular, as compared to cells injected with a variety of other plasmamembrane-associated proteins. This can be observed by comparing the cells injected with PLD2 (Fig. 6c ) to ones injected with activated human ras (Fig. 6e) . Activated Ras Preferential inhibition of PLD2 by a heat-stable factor from brain. Extracts were prepared from bovine brain cytosol, heat-denatured at 70°C, and fractionated using column chromatography as described in Materials and methods. (a) The fraction used in this experiment contained a major detectable protein of about 18 kDa, as well as minor quantities of several other, larger proteins. Several preparations of equivalent fractions have been generated and each exhibits identical properties. (b) PLD2 activity was measured using a standard headgroup assay as in Figure 3 , in the presence of increasing amounts of inhibitor. The inhibition of both isoforms of PLD1 (PLD1a and PLD1b, as described in Materials and methods) was determined in the presence of ARF because PLD1 does not have significant basal activity, so the effect of the inhibitor on isolated PLD1 cannot be assessed. The identity and mechanism of action of the inhibitor are not known, although the selectivity for PLD2 over PLD1, as well as other studies (data not shown), rules out the possibility that the inhibitor degrades, sequesters or otherwise modifies either the phosphatidylcholine substrate or the polyphosphoinositide cofactors present in the assays. Identical results for PLD2 were observed in the presence or absence of either ARF1 and/or GTP␥S. also accumulated at the plasma membrane, but did not induce the formation of the ventral cellular projections observed in the PLD2-overexpressing cells. A small number of filopodia were also observed in the PLD2-overexpressing cells.
Serum stimulation of PLD2-injected cells resulted in an altered cortical appearance that is most readily apparent as almost continuous filopodium-like projections from the cell surface, and accumulation of PLD2 in restricted regions at the cell edge (Fig. 6d) . In addition, redistribution of PLD2 from the plasma membrane to submembranous vesicles was observed. A similar response was not observed in cells injected with activated human ras (Fig. 6f) ; the plasma membrane remained relatively regular and no redistribution of Ras was observed. The mechanism by which serum stimulation enhanced the cortical reorganization induced by PLD2 overexpression is not known. We cannot measure the degree to which PLD2 was active in the microinjected cells, and it is possible that the serum stimulation resulted in heightened activation of PLD2 through effects on PLD2 or cofactors such as PIP 2 . Alternatively, serum stimulation might activate other pathways that synergize with PLD2 to result in the observed cellular response.
Research Paper Mammalian phospholipase D2 Colley et al. 197
Figure 6
Subcellular localization and overexpression phenotypes of PLD1 and PLD2. Expression vectors encoding influenza-epitope-tagged (a,b) PLD1, (c,d) PLD2 and (e,f) Ras were microinjected into confluent, serum-starved rat embryo fibroblasts (REF-52) using established methods [41] . In some cases (b,d,f), the cells were additionally stimulated by serum. Cells were fixed 6-24 h after microinjection and immunostained using a monoclonal antibody (12CA5) directed against the epitope tag. The tagged proteins were visualized under fluorescence to detect the Texas Red-labeled secondary antisera. (a) PLD1 was detected in a peri-nuclear region in a complex pattern. Non-injected cells present in the field are not observed under fluorescent illumination, demonstrating the specificity of the immunodetection. C 6 -NBD-ceramide, a lipid that localizes to the Golgi, overlapped with a subset of the PLD1 pattern (data not shown). However, the extended region in which PLD1 is localized is more consistent with the ER, and the vesicular structures observed near the nucleus appear similar to late endosomes [49] . Cortical reorganization mediated by actin polymerization has also been shown to be directed by the small GTPbinding proteins Rac, Rho and Cdc42, which regulate the formation of membrane ruffles, lamellipodia and filopodia [10] . As Rho family members do not activate PLD2 in vitro, it is not immediately apparent where PLD2 fits into the scheme of cortical reorganization processes mediated by the Rho family. On the other hand, preparations of plasma membrane contain an endogenous PLD activity that is activated by ARF and Rho [15, 16] . It is not clear at present whether PLD2 is responsible for this reported activity; it is possible that this activity represents a third, novel PLD isoform. Alternatively, at physiological concentrations and in the endogenous setting (in the presence of inhibitors or rate-limiting cofactors such as PIP 2 ), PLD2 activity may be directly or indirectly regulated by Rho family members through an unknown mechanism. Although the relationship between PLD2 and the pathways effected by the small GTP-binding proteins remains to be clarified, the observations made using microinjection demonstrate that PLD2 is likely to represent a significant factor in the morphological response to transduced signals.
The redistribution of PLD2 into submembranous vesicles is also intriguing. This is clearly not a passive effect of serum stimulation, as human Ras, which is also plasmamembrane localized, does not become redistributed. A number of recent reports have implicated ARF and members of the Rho family in receptor-mediated endocytosis. ARF6 is located on the plasma membrane in quiescent cells and becomes redistributed in a similar manner during receptor-mediated endocytosis of transferrin [44] . RhoA, RhoD and Rac1 have also been shown to play a role in this process [45, 46] . Involvement of PLD2 in this pathway is an attractive hypothesis, since endocytic recycling is functionally analogous in several respects to PLDpromoted budding from the Golgi complex.
Conclusions
Numerous agonists, ligands, and growth factors have been reported to activate PLD subsequent to triggering Gprotein-coupled or tyrosine kinase receptors, and a PLD1-like enzyme has been assumed to account for this activity [1] . We suggest that PLD2 may account for a significant part of the reported activity. Key issues to address include determining whether endogenous PLD2 is activated by receptor stimulation in vivo, and to what extent this accounts for the cellular response to external signals. Despite having different subcellular locations and modes of regulation, PLD1 and PLD2 may act in concert. Growing evidence suggests that regulated secretion triggered by external signals can result in vesicle translocation and the release of secretagogues in a polarized manner towards the inducing signal [6, 47] , which is consistent with there being distinct and coordinated roles for the two enzymes. We propose that PLD1 plays a role in the formation and initial translocation of vesicles from the peri-nuclear region. As one possibility, PLD2 may play a role in the cytoskeletal reorganization that results in directed movement of the vesicles. Alternatively, activation of PLD2 may lead to subsequent activation of PLD1 through the generation of PA which could then be hydrolyzed to DAG and activate PKC.
Taken together, our findings reveal for the first time a form of PLD that exhibits an unexpected type of regulation and that can induce changes in cell morphology. In addition, the results suggest the existence of a novel class of molecules -PLD2 inhibitors -that are likely to be involved in the control of signal transduction propagation; these inhibitors complement the PKCs and GTP-binding proteins that have previously been reported to activate PLD1. Previous models for the roles of PLD enzymes will need to be re-evaluated in the light of these results.
Materials and methods
Molecular isolation of mouse PLD2
Partial mouse PLD2 (mPLD2) cDNAs were obtained from ZAP II embryonic day 10.5 mouse embryo and neonatal brain cDNA libraries (Stratagene, Inc.) as described in the text. The 20 mPLD2 cDNA clones sequenced (Sequenase Version 2.0, United States Biochemicals; a final sequence was determined from both strands) had approximately 2.4 kb of coding and 3′ untranslated region (UTR) sequence but lacked 5′ coding and 5′ UTR sequences. The 5′ sequence was obtained using RACE PCR [30] . The mPLD2 aminoacid and nucleotide sequences have been deposited in Genbank under the accession number U87557. There are no unusual features in the nucleotide sequence. The 3491-nucleotide sequence is likely to be nearly full length, since the mPLD2 mRNA is approximately 3.5 kb as determined by northern blot analysis (data not shown). The presumed initiator methionine (nucleotides 138-140) conforms to the eukaryotic consensus sequence and is the first in-frame methionine in the 5′ UTR. The coding region is additionally thought to be full length since an in-frame stop codon is located at nucleotides 58-60 of the cDNA. The entire 3′ UTR (557 nucleotides) was presumably obtained, since a recognizable polyadenylation signal sequence is present starting 19 nucleotides before the 3′ end of the composite cDNA.
Preparation of affinity-purified PLD2 anti-peptide antibodies
Peptides corresponding to residues 29-39 and 476-486 of the sequence of mPLD2 were prepared, conjugated to keyhole limpet hemocyanin, suspended in saline, and emulsified with Freund's adjuvant. Two rabbits were immunized with the peptide corresponding to residues 29-39, and two additional rabbits were immunized with the peptide corresponding to residues 476-486, by subcutaneous injection. After a second immunization, serum was obtained from the animals and antibody titers determined by enzyme-linked immunosorbent assay using the individual peptide antigens as the solid phase. PLD2-specific antibodies were affinity-purified from serum obtained from the animals with the highest antibody titers, using affinity chromatography in which the immobilized peptide antigens were employed as the solid phase. The purified antibodies were adjusted to approximately 1 mg ml -1 and stored as aliquots in buffer containing 10 mM NaPO 4 2-, 20 mM NaCl and 0.1 mM NaN 3 at -80°C. These antibodies recognize PLD2 by western blotting and can immunoprecipitate PLD2 under denaturing and non-denaturing conditions. The peptide antigens were chosen to generate antibodies that can distinguish PLD2 from PLD1 (see Fig. 1 ). The peptide antisera were prepared by Quality Controlled Biochemicals Corporation, Hopkinton, Massachusetts.
Preparation of immunoaffinity resin
A mixture of the two affinity-purified antibodies (1 mg) was adsorbed to 0.5 ml of protein A coupled to Sepharose-CL4B (Sigma) in phosphatebuffered saline (PBS) for 1 h at room temperature. The resin was washed with 0.2 M sodium borate, pH 9.0, and the antibodies covalently linked to the immobilized protein A by reaction with 20 mM dimethylpimelimidate in 0.2 M sodium borate, pH 9.0 for 30 min at room temperature with constant agitation. The reaction was quenched by washing the resin in 0.2 M ethanolamine, pH 8, after which the resin was washed in 100 mM glycine pH 3.0 to remove antibodies that were not covalently attached. The resin was then washed extensively and stored in PBS containing 0.1% NaN 3 .
Expression and purification of activator and PLD proteins
The expression and purification of recombinant PLD1, ARF, RhoA and PKC␣ have been described in detail previously [20, 21] . As described elsewhere, there are two isoforms of PLD1, differing in inclusion (PLD1a) or exclusion (PLD1b) of a 38 amino-acid exon in the PLD1-specific loop region [21] . To date, PLD1a and PLD1b have exhibited identical properties. Both PLD1a and PLD1b were used for the experiments described in this paper.
The mPLD2 cDNA was inserted into the unique SmaI and Not I sites of the pVL1392 transfer vector (Invitrogen Inc.), and recombinant baculoviruses harboring the cDNA were generated, selected and propagated using standard methods [20, 21, 48] . In brief, monolayers of sf9 insect cells were transfected with a mixture of the PLD2 transfer vector and linearized wild-type baculovirus DNA. Recombinant baculoviruses were plaque-purified from media removed from these transfected cells. The pure viruses were amplified by infection of suspension cultures of sf9 cells and the high-titer virus stocks obtained were stored at 4°C.
To express PLD2, monolayers of exponentially growing sf9 cells (3 × 10 7 cells per 225 cm 2 flask; generally two flasks of cells for each purification) were infected with recombinant baculoviruses at a multiplicity of 10 for 1 h with gentle rocking. After the 1 h infection, the viruscontaining medium was removed and replaced with fresh supplemented Grace's medium. The infected cells were grown for 48 h, the media removed, and the cells washed once with ice-cold PBS. The cells were lysed on ice by addition of 5 ml per 225 cm 2 flask of ice-cold lysis buffer containing 150 mM NaCl, 50 mM Tris, pH 8.0, 1% Nonidet P-40, 1 mM EGTA, 0.1 mM benzamidine, 0.1 mM PMSF, 10 mg ml -1 pepstatin A, and 10 mg ml -1 leupeptin. After 30 min on ice, the cells were scraped up and the suspension centrifuged at 50 000 g for 30 min at 4°C. The supernatant obtained (10 ml, containing approximately 45 mg protein) was mixed with 0.5 ml anti-PLD2 immunoaffinity resin (see above) and kept at 4°C with constant agitation on a rotary platform for 1 h. The resin was then sedimented by gentle centrifugation (500 g × 3 min) and the supernatant containing unbound proteins removed, following which the resin was washed three times with 25 volumes of lysis buffer. After the final wash, the resin was resuspended in 5 ml of lysis buffer and transferred to a 10 ml BioRad disposable chromatography column. The resin was then washed with 10 ml 10 mM phosphate buffer, pH 6.8, containing 1% ␤-D-octylglucoside (␤-DOG). Bound protein was eluted using 100 mM glycine, pH 3.0, containing 1% ␤-DOG. Application of three 0.5 ml aliquots of elution buffer sufficed to elute all of the PLD2. The eluant was collected as separate 0.5 ml fractions on ice into tubes containing 0.075 ml 1 M phosphate buffer, pH 8.0. Fractions recovered from the immunopurification were tested for activity and examined by SDS-PAGE and western blotting using standard procedures, as shown in Figure 2 . By Coomassie blue staining, silver staining, and western blot analysis, PLD2 was the only detectable protein present after purification. Although the presence of trace amounts of contaminating proteins cannot be rigorously ruled out, no other protein was present in anything approaching stoichiometric quantities. The immunopurification procedure was also carried out for sf9 cells expressing an unrelated phospholipase C protein (details in [21] ). No visible protein was recovered and no fraction exhibited PLD activity in the standard in vitro assay.
Approximately 10 mg PLD2 was recovered from two 225 cm 2 flasks, which corresponds to a 20-30% yield of the PLD2 activity present in the starting sf9 cell detergent extract (PLD activity in the detergent extracts was determined after detergent removal by gel-filtration chromatography). Purified PLD2 had a specific activity of approximately 9 mmol min -1 mg -1 under our standard assay conditions. Although the most effective extraction of the protein requires detergent treatment, approximately 50% of the membrane-bound PLD2 activity can be extracted with 0.5 M NaCl. However, in the absence of detergents, enzyme activity is less stable. The purified protein is kept at 4°C in buffer containing 1% ␤-DOG and is stable for several days.
PLD assays
The basic PLD in vitro assay was performed as described previously using headgroup-labeled phosphatidylcholine [20, 21, 32] . Approximately 10 ng PLD2 was used for each assay sample. Purified small GTP-binding proteins and PKC␣ were included in some of the experiments, as described previously [21] . The small GTP-binding proteins were preloaded with GTP␥S after EDTA-mediated stripping as described previously [21] . PKC␣ was activated in the assay tube by the addition of PMA to a final concentration of 100 nM. ATP was not present in the assay tubes to which PKC␣ was added. In general, reagents were mixed on ice and reactions initiated by transfer to a 37°C water bath. Choline release varied linearly over time and in proportion to the amount of protein added.
PLD assays in vivo were performed exactly as described elsewhere [33] . For transient transfection experiments, an influenza-epitope tag was appended to the amino terminus of PLD2 and expression of the hybrid RNA was driven by the CMV promoter (the same vector was used previously to achieve transient transfection of PLD1; see [20] ). Using lipofectamine, a typical transfection efficiency of 5-10% of the subconfluent COS-7 cells present in a dish was observed. Recombinant protein was visualized by either immunofluorescence or western blotting using the commercially available monoclonal antibody 12CA5 (Boerhinger Mannheim). After transfection of a 35 mm plate of subconfluent COS-7 cells, PLD1 and PLD2 could be detected easily by western blotting of 10% of the transfected cells. The relative amounts of protein expressed were difficult to quantitate because PLD1 has a tendency to become trapped at the interface between the stacking and resolving gels to a variable extent [21] . No obvious differences in specific activities or in responses to activators were observed for the native PLDs (1 and 2) produced using baculovirus compared to the epitopetagged PLDs produced in COS-7 cells.
Enrichment of the PLD2-specific inhibitor
In brief, bovine brain tissue was homogenized in fresh ice-cold TED (20 mM Tris, pH 8.0, 1 mM EDTA, 1 mM DTT) buffer containing protease inhibitors. The homogenate was spun for 45 min at 20 000 g to pellet most of the membrane fraction. The supernatant was harvested and spun further for 60 min at 100 000 g to pellet the remaining particulate material. The clarified supernatant was then incubated at 70°C for 45 min. Denatured proteins were removed by centrifugation for 30 min at 100 000 g, and the supernatant concentrated 25-fold by pressure filtration. The concentrate was applied to a 500 ml Sephacryl S-300 HR gel-filtration column equilibrated with TED buffer. Fractions (6 ml) were collected after the void volume (150 ml) had passed. Two peaks of inhibitory activity were observed, the second of which (fractions 27-38) exhibited a PLD2-specific activity. These fractions were then applied to a Source 15Q (Pharmacia) column equilibrated with TED buffer and eluted with a 100 ml gradient of 0-400 mM NaCl, collecting 2 ml fractions. Three peaks of inhibitory activity were detected, the third of which (fractions 28-35) contained the PLD2-specific inhibitory activity. These fractions were concentrated by pressure filtration, transferred into HED buffer (20 mM HEPES, pH 7.4, 1 mM EDTA, 1 mM DTT), and applied to a 5 ml heparin-Sepharose (Pharmacia) column. The column was eluted with a 50 ml gradient of 0-500 mM NaCl, collecting 1 ml fractions. Fractions 9-20 contained an activity which strongly and specifically inhibited PLD2. Fractions were pooled, concentrated as above, and stored at -80°C. The preparation contained a protein of approximately 18 kDa as assessed by SDS-PAGE, with a purity of > 95% as assessed by Coomassie staining.
Microinjection of PLD expression plasmids
Microinjections were carried out as described previously [41] using influenza-epitope-tagged PLD proteins expressed under the control of a CMV promoter. Cells were fixed 6-24 h after microinjection and analyzed immunohistochemically to detect the expressed proteins. A commercial monoclonal antibody, 12CA5 (Boerhinger Mannheim), was used to detect the influenza (HA) tag. HA epitope tagging is widely used to determine protein localization and the epitope is not thought to influence subcellular localization. Nonetheless, until confirmed by detection of the endogenous proteins, it remains a formal possibility that the epitope or overexpression itself may influence the subcellular localization observed.
Because Current Biology operates a 'Continuous Publication System' for Research Papers, this paper has been published via the internet before being printed. The paper can be accessed from http://biomednet.com/cbiology/cub.htm -for further information, see the explanation on the contents page.
